The Management of Preterm Labor with the Calcium Channel-Blocking Agent Nifedipine Combined with the β-Mimetic Terbutaline

1985 ◽  
Vol 19 (5) ◽  
pp. 369-371 ◽  
Author(s):  
Alan F. Kaul ◽  
Rapin Osathanondh ◽  
Leonard E. Safon ◽  
Fredric D. Frigoletto ◽  
Paul A. Friedman
Keyword(s):  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Preterm Labor ◽  
Case Reports ◽  
Blocking Agent ◽  
Channel Blockers ◽  
Channel Blocking

We describe a successful, prolonged, inhibition of preterm labor using nifedipine combined with terbutaline in a patient undergoing complicated obstetrical problems. Delivery was delayed for two months and no significant ill effects were observed in the mother or her infant. This case reports the longest duration and the safe use of nifedipine for tocolysis, to date. A review of reports of the use of calcium channel-blockers in preterm labor is also presented.

Calcium channel blockers in the management of preterm labor and hypertension in pregnancy

2001 ◽  
Vol 97 (2) ◽  
pp. 122-140 ◽  
Author(s):  
Dimitrios N.M. Papatsonis ◽  
Christianne A.R. Lok ◽  
Jacqueline M. Bos ◽  
Herman P.van Geijn ◽  
Gustaaf A. Dekker
Keyword(s):  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Preterm Labor ◽  
Channel Blockers ◽  
Hypertension In Pregnancy ◽  
In Pregnancy

Calcium Metabolism, Calcium-Channel Blocking Agents, and Hypertension Management

1988 ◽  
Vol 22 (9) ◽  
pp. 659-671 ◽  
Author(s):  
Y.W. Francis Lam
Keyword(s):  
Calcium Channel ◽  
Systemic Vascular Resistance ◽  
Vascular Resistance ◽  
Calcium Channel Blockers ◽  
Calcium Metabolism ◽  
Antihypertensive Agents ◽  
Channel Blockers ◽  
Blocking Agents ◽  
Calcium Channel Blocking Agents ◽  
Channel Blocking

Increasing evidence has suggested that a disturbance of cellular calcium metabolism may have a role in initiating and maintaining elevated systemic vascular resistance in essential hypertension. Controversy exists over whether calcium can alleviate or exacerbate the hypertensive process, and diversity of calcium metabolism in hypertensive patients has been proposed. Calcium-channel blocking agents are potent vasodilators capable of correcting the elevated systemic vascular resistance. Clinical studies have shown that these drugs have antihypertensive efficacy comparable to established agents. The elderly, blacks, and patients with low renin activity respond well to calcium-channel blockers. These drugs may also offer potential advantages over established antihypertensive agents in patients with other coexisting diseases. Sustained release formulations have been developed, and initial experience with long-term efficacy and tolerability is encouraging. The calcium-channel blockers may become first-line therapy for treatment of hypertension in selected patients.

Are Calcium-Channel Blockers Effective in the Treatment of Tardive Dyskinesia?

1993 ◽  
Vol 27 (2) ◽  
pp. 191-196 ◽  
Author(s):  
Marshall Cates ◽  
Kim Lusk ◽  
Barbara G. Wells
Keyword(s):  
Tardive Dyskinesia ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Case Reports ◽  
Response To Treatment ◽  
Channel Blockers ◽  
Medical Subject Headings ◽  
Double Blind ◽  
Medline Search ◽  
Mesh Terms

Objective To review the data describing the use of calcium-channel blockers in the treatment of tardive dyskinesia (TD). Data Sources A MEDLINE search of the English-language literature and a bibliographic review of pertinent articles examining the use of calcium-channel blockers in the treatment of TD were performed. Medical Subject Headings (MESH) terms used were calcium-channel blockers, tardive dyskinesia, nifedipine, verapamil, and diltiazem. STUDY SELECTION AND DATA EXTRACTION Relevant case reports, open trials, and controlled studies reporting on the efficacy of calcium-channel blockers for treating TD are reviewed. Appropriate conclusions are drawn from the data and guidelines are suggested for the practitioner. Data Synthesis Studies addressing the efficacy of calcium-channel blockers in the palliative treatment of TD have yielded mixed results. Positive findings have been reported for nifedipine, verapamil, and diltiazem; nifedipine may be the most efficacious treatment and diltiazem the least. It appears that patients with TD who can tolerate higher doses of calcium-channel blockers may respond more favorably to treatment. Patient characteristics that may help determine a better response to treatment with calcium-channel blockers include advanced age and more-severe TD. Conclusions To determine the efficacy of calcium-channel blockers in the treatment of TD, additional data are needed from double-blind, placebo-controlled studies with larger sample sizes and longer durations of treatment. Until these data are available, calcium-channel blockers should be considered potentially useful therapy for the heretofore unresponsive TD.

scholarly journals In silico Analysis on hERG Channel Blocking Effect of a Series of T-type Calcium Channel Blockers

2011 ◽  
Vol 32 (1) ◽  
pp. 251-262
Author(s):  
Jae-Wan Jang ◽  
Chi-Man Song ◽  
Kee-Hyun Choi ◽  
Yong-Seo Cho ◽  
Du-Jong Baek ◽  
...  
Keyword(s):  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
In Silico ◽  
In Silico Analysis ◽  
Blocking Effect ◽  
Herg Channel ◽  
Channel Blockers ◽  
Channel Blocking ◽  
Silico Analysis

scholarly journals Hypoglycemia After Gastric Bypass Successfully Treated With Calcium Channel Blockers: Two Case Reports

2019 ◽  
Vol 3 (7) ◽  
pp. 1417-1422 ◽  
Author(s):  
Angharad Ames ◽  
Carlos A Lago-Hernandez ◽  
Eduardo Grunvald
Keyword(s):  
Gastric Bypass ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Case Reports ◽  
Nutrition Therapy ◽  
Hyperinsulinemic Hypoglycemia ◽  
Channel Blockers ◽  
Dietary Interventions ◽  
Obesity Epidemic ◽  
Poor Tolerance

Abstract Postprandial hyperinsulinemic hypoglycemia is an uncommon yet well-established complication of Roux-en-Y gastric bypass (RYGB) that can result in serious morbidity and adversely affect quality of life. It is often unrecognized and may be difficult to diagnose. Management is challenging. As the number of bariatric procedures increases in parallel with the obesity epidemic, clinicians will be tasked to offer effective medical therapies for this complication. Two patients presented several years after RYGB with severe postprandial hypoglycemia. In one of the patients, we were able to document simultaneous postprandial hypoglycemia and hyperinsulinemia. Conventional treatment approaches, including medical nutrition therapy, acarbose, diazoxide, and octreotide, were either ineffective or limited by poor tolerance. Nifedipine and verapamil were used adjunctively with dietary modification, resulting in resolution of symptomatic hypoglycemic episodes. These agents are therapeutic options that can be used for some patients refractory to more traditional treatments. They should be tried before surgical procedures are considered for affected patients. These two cases demonstrate that calcium channel blockers may be efficacious and appropriate for select patients refractory to dietary interventions alone.

Sign in / Sign up

Export Citation Format

Share Document